Literature DB >> 1752784

Prognostic significance of circulating immune complexes in cancer patients.

T K Dass1, M Aziz, A Rattan.   

Abstract

Circulating immune complexes (CIC) were estimated in 100 cancer patients and 25 healthy control volunteers by means of the polyethylene glycol (PEG) precipitation test and latex agglutination inhibition (LAI) test. Pathological levels of CIC were found in 47% of the patients by PEG precipitation test and in 59% of the patients by LAI test; both tests were positive in 33% of the patients. Consequently, the use of the two assays resulted in 73% seropositivity for CIC. The PEG precipitation test detects antigen-antibody complexes formed in the ratio of 2:1 (Ag2Ab), while the LAI test could detect immune complexes formed over an extended range of antigen-antibody ratio including complexes as small as 8S. CIC values were significantly higher by combined assays (P less than 0.001) as compared to individual assays (P less than 0.01) when compared with the control group. It was found that 75% of post-operative follow-up patients became seronegative for CIC in the combined assays, whereas the 25% of post-operative patients who remained seropositive for CIC showed recurrence within three months after surgery. Immune-complex deposition was demonstrated on malignant cells in vitro by direct immunofluorescence studies in 73.3% of patients, while 60% of patients revealed complement-fixing antigen-antibody complexes. It was found that 20% of patients showing positive immunofluorescence with anti-C3-antisera had decreased levels of CIC. Complement-mediated cytotoxic injury results in reduction of tumor cell mass and subsequent decrease in CIC. Necrotizing and leucocytoclastic vasculitis in the tumor mass was initiated by raised CIC levels in vivo in 71% of patients. Necrosis of malignant tumors was seen in 58% of patients, and hemorrhage in 36% of patients. These changes were considered to be an aftermath of immuno-complex vasculitis initiated by CIC.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1752784      PMCID: PMC5918336          DOI: 10.1111/j.1349-7006.1991.tb01794.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


circulating immune complexes standard deviation polyethylene glycol third component of complement latex agglutination inhibition fluorescein isothiocyanate immunofluorescence
  27 in total

1.  Isothiocyanate compounds as fluorescent labeling agents for immune serum.

Authors:  J L RIGGS; R J SEIWALD; J H BURCKHALTER; C M DOWNS; T G METCALF
Journal:  Am J Pathol       Date:  1958 Nov-Dec       Impact factor: 4.307

2.  The nature of immune complexes in human cancer sera.

Authors:  A N Theofilopoulos; B S Andrews; M M Urist; D L Morton; F J Dixon
Journal:  J Immunol       Date:  1977-08       Impact factor: 5.422

3.  The specificity and polyvalency of binding of a monoclonal rheumatoid factor.

Authors:  R Eisenberg
Journal:  Immunochemistry       Date:  1976-04

4.  [Sequential determination of circulating immune complexes in ovarian tumors].

Authors:  F Beaufort; H Auner; M Lahousen
Journal:  Wien Med Wochenschr       Date:  1986-07-15

5.  The L1210 assay for immune complexes: application in cancer patients and correlation with disease progress.

Authors:  P K Poskitt; T R Poskitt
Journal:  Int J Cancer       Date:  1979-11-15       Impact factor: 7.396

6.  Evaluation of different methods for detecting circulating immune complexes. Studies in patients with lung cancer.

Authors:  G Füst; B Fekete; I Angyal; A Jakab; A Pál; K Merétey; A Falus; K Török; G Szegedi; M Kávai; E Puskás; M Csécsi-Nagy; T Szabó; A Lenkey; M Misz
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

7.  Report on international comparative evaluation of possible value of assays for immune complexes for diagnosis of human breast cancer.

Authors:  R B Herberman; M Bordes; P H Lambert; H S Luthra; R A Robins; P Sizaret; A Theofilopoulos
Journal:  Int J Cancer       Date:  1981-05-15       Impact factor: 7.396

8.  Detection of circulating immune complexes in patients with squamous cell carcinoma of the oral cavity.

Authors:  R Mukhopadhyaya; R S Rao; A R Fakih; S G Gangal
Journal:  J Clin Lab Immunol       Date:  1986-12

9.  Clinical relevance of circulating immune complexes in human leukemia. Association in acute leukemia of the presence of immune complexes with unfavorable prognosis.

Authors:  N A Carpentier; G T Lange; D M Fiere; G J Fournie; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

10.  Localization of antigen in tissue cells; improvements in a method for the detection of antigen by means of fluorescent antibody.

Authors:  A H COONS; M H KAPLAN
Journal:  J Exp Med       Date:  1950-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.